Condition
Horner Syndrome
Total Trials
3
Recruiting
0
Active
0
Completed
1
Success Rate
33.3%-53% vs avg
Key Insights
Highlights
Success Rate
33% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 55/100
Termination Rate
66.7%
2 terminated out of 3 trials
Success Rate
33.3%
-53.2% vs benchmark
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results33% success
Data Visualizations
Phase Distribution
1Total
P 4 (1)
Trial Status
Terminated2
Completed1
Trial Success Rate
33.3%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT03615508Phase 4TerminatedPrimary
Exploration of Pupil Dilation in Horner's Patients Taking Flomax
NCT04642612Terminated
Cerebral Blood Flow Evaluation With Trancranial Doppler After Interscalene Nerve Block
NCT03514342Completed
The Effects of Horner's Syndrome Developing After Interscalene Brachial Plexus Block on Autonomic Nervous Activity
Showing all 3 trials